| abstract |
The present invention relates to a pharmaceutical composition for the treatment of diseases related to a drug addiction containing from 250 to 500 mg of naltrexone, preferably 300 to 400 mg of naltrexone, and most preferably 380 mg of naltrexone, and 700 to 3500mg, preferably 1000 to 2000mg, more preferably 1540mg of topiramate where the active pharmaceutical ingredients (API's) are formulated as depot on PLGA polymer base (polylactic glycolic acid), whose ratio should be 75:25 (75% lactic acid and 25% glycolic acid). |